Answers are grounded in this paper and cite their sources.
Case report reveals increased platelet counts following oseltamivir phosphate in a child with immune thrombocytopenic purpura, suggesting potential therapeutic benefits of neuraminidase inhibitors.
We report a pediatric patient with chronic idiopathic thrombocytopenic purpura who suffered from an influenza A (H1N1) virus infection. A 13-year-old girl presented with fever, coughing, and generalized petechiae. The influenza A antigen was positive in her pharyngeal aspirate. She was successfully treated with neuraminidase inhibitor oseltamivir phosphate. Her platelet counts progressively increased with oseltamivir phosphate without another blood product or agent. We suggest that oseltamivir phosphate can be used in patients with immune thrombocytopenic purpura who present with influenza virus A infection. We also suggest that oseltamivir phosphate can be effective in patients with immune thrombocytopenic purpura. Large study groups are needed to confirm the relationship between idiopathic thrombocytopenic purpura and neurominidase inhibitors.
No takes yet. Share an insight, caveat, or question.
Alioğlu et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: